Grants Notice For Seamless Early-Stage Clinical Drug Development (Phase 1 To 2A) For Noveltherapeutic Agents For The Spectrum Of Alzheimers Disease (Ad) And Ad-Relateddementias (Adrd) (Ug3/Uh3 Clinical Trial Required

Seamless Early-Stage Clinical Drug Development (Phase 1 To 2A) For Noveltherapeutic Agents For The Spectrum Of Alzheimers Disease (Ad) And Ad-Relateddementias (Adrd) (Ug3/Uh3 Clinical Trial Required The Purpose Of This Notice Of Funding Opportunity (Nofo) Is To Invite Applications That Bundle Independent Protocols For Phase 1 Clinical Trials With Phase 1B/Phase 2A Clinical Trials To Streamline The Early-Stage Evaluation Of Promising Pharmacological Interventions For Alzheimers Disease (Ad) And Alzheimers Disease-Related Dementias (Adrd). Candidate Interventions Evaluated Through This Program, Which Can Include Small Molecules Or Biologics For Example, Must Engage Non-Amyloid/Non-Tau Mechanisms And Aim To Address Cognitive And/Or Neuropsychiatric Symptoms In Individuals Across The Spectrum From Pre-Symptomatic To More Severe Stages Of Disease. This Nofo Uses The Ug3/Uh3 Phased Award Mechanism And Proposals Must Include Prespecified, Go/No-Go Safety And Tolerability Milestones That Gate The Advance From Phase 1 To Latter Stages Of Clinical Development